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In a recent paper in Nature, Barber et al. (2005) show that the immunoreceptor PD-1 is 
upregulated by “exhausted” T cells during the chronic phase of viral infection in mice. 
Remarkably, blocking the interaction between PD-1 and its ligand, PD-L1, reactivates these 
T cells and reduces viral load.The protein PD-1 (programmed cell 
death 1) was originally isolated from a 
thymic T cell line that showed increased 
expression of this protein following 
stimuli that promote apoptosis (Ishida 
et al., 1992). PD-1 belongs to the CD28 
family of immunoreceptors and is 
expressed by activated T, B, and mye-
loid cells. Upon interaction with either 
of two ligands, PD-L1 or PD-L2, PD-1 
inhibits antigen stimulation of T and B 
cells by recruiting the protein tyrosine 
phosphatase, SHP-2. PD-1 signaling is 
known to be involved in autoimmunity, 
allergy, sites of immune privilege, and 
antitumor immunity (Figure 1). In work 
recently published in Nature, Barber 
et al. (2005) now show that increased 
PD-1 expression is a mechanism by 
which CD8 T cells become functionally 
impaired during chronic viral infection. 
This work shows that blocking PD-1 
signaling diminishes persistent viral 
infection in mice and may lead to new 
treatments for chronic viral infections 
in humans.
The best evidence that PD-1 sup-
presses immune activation comes 
from PD-1-deficient mice, which 
develop autoimmune diseases (Oka-
zaki et al., 2002). Single-nucleotide 
polymorphisms at the PD-1 locus 
have also been identified in human 
patients with autoimmune disorders 
such as systemic lupus erythemato-
sus, rheumatoid arthritis, and type 
I diabetes (Prokunina and Alarcon-
Riquelme, 2004). Both tumors and 
pathogens take advantage of the inhibitory signal through PD-1 to pro-
mote their survival in the host. Indeed, 
adenovirus can be eliminated more 
efficiently when PD-1 is absent (Iwai 
et al., 2003). However, the precise 
mechanism by which PD-1 regulates 
antiviral immunity is not known.
In their recent work, Ahmed and 
colleagues (Barber et al., 2005) dis-
sect the function of PD-1 in acute and 
chronic viral infection in mice. They use 
two different strains of lymphocytic 
choriomeningitis virus (LCMV): the 
Armstrong strain that is cleared within a 
week and the clone 13 strain that estab-
lishes a persistent infection. Ahmed Cell 124, Feand colleagues previously demon-
strated that many of the LCMV-specific 
CD8 T cells are functionally impaired, 
or exhausted, in the chronic phase of 
LCMV-clone 13 infection (Zajac et al., 
1998). Although these LCMV-specific 
CD8 T cells express activation mark-
ers such as CD69 and CD44, they 
lack antiviral effector functions. In the 
new work, Barber et al. (2005) reveal 
that PD-1 is highly expressed on the 
exhausted LCMV-specific CD8 T cells 
and that blocking the PD-1/PD-L1 
interaction during the chronic phase 
of infection efficiently reanimates 
exhausted CD8 T cells and promotes 
Figure 1. Role of PD-1 in Multiple  
Immune Responses
Depicted is an antigen-presenting dendritic 
cell and a CD8 T cell. PD-1 is expressed on 
activated T, B, and myeloid cells. The PD-lig-
and 1 (PD-L1) is expressed on T cells, B cells, 
macrophages, and dendritic cells as well as on 
nonlymphoid parenchymal cells, whereas PD-
L2 is expressed on activated macrophages and 
dendritic cells. Upon antigen stimulation by cells 
expressing the major histocompatibility complex 
(MHC) and a PD-1 ligand, the tyrosine-based 
switch motif of PD-1 is phosphorylated. This is 
followed by recruitment of the protein tyrosine 
phosphatase SHP-2. SHP-2 dephosphorylates 
downstream effector molecules of the antigen 
receptor including Syk, ZAP70, and PI3K to 
inhibit the activation of lymphocytes. PD-1-de-
pendent inhibition is involved in autoimmune 
diseases (such as systemic lupus erythemato-
sus, type I diabetes mellitus, and rheumatoid ar-
thritis), infection (by both viruses and parasites), 
allergy (asthma and delayed-type hypersensitiv-
ity), immune privilege (feto-maternal tolerance), 
antitumor immunity (including glioma, leukemia, 
and cancers of the kidney, esophagus, lung, 
and ovary), and transplantation immunity (in 
heart and islet transplants, and in graft-versus-
host disease).bruary 10, 2006 ©2006 Elsevier Inc. 459
clearance of the persisting virus. By 
contrast, in acute LCMV-Armstrong 
infection, PD-1 expression is tran-
siently induced and declines quickly to 
basal levels. The viruses are cleared in 
a week, and blocking the PD-1/PD-L1 
interaction does not affect the number 
of LCMV-specific CD8 T cells (Barber 
et al., 2005). Although the absence of 
helper CD4 T cells further suppresses 
the activation of CD8 T cells during 
chronic viral infection (Zajac et al., 
1998), blocking the PD-1/PD-L1 inter-
action reanimates CD8 T cells even in 
the absence of CD4 T cells. Therefore, 
blocking the activity of PD-1 may be a 
particularly useful treatment for HIV-
infected patients who have very low 
numbers of CD4 T cells.
How does PD-1 signaling induce 
exhaustion of CD8 T cells? To answer 
this question, it is essential to know 
which cells provide the ligand for PD-1. 
Although high expression of PD-L1 is 
found on LCMV-infected splenocytes, 
it is not documented whether PD-L1-
positive cells can act as antigen-pre-
senting cells or target cells. Probst 
et al. (2005) have recently demon-
strated that the presentation of peptide 
epitopes of LCMV by resting dendritic 
cells induces CD8 T cell tolerance in 
a PD-1-dependent manner. Because 
clone 13, but not Armstrong, LCMV 
infects antigen-presenting dendritic 
cells (Sevilla et al., 2000), exhaustion 
of CD8 T cells is likely to be induced 
by PD-L1-expressing dendritic cells 
infected by LCMV-clone 13. Recent 
work by Kirchberger et al. (2005) dem-
onstrates that human rhinovirus infec-
tion specifically induces PD-L1 and 
sialoadhesin expression on the surface 
of dendritic cells. These dendritic cells 
then suppress allogenic T cells into a 
hypoproliferative state that cannot be 
reversed by the addition of exogenous 
interleukin-2 (IL-2). It is possible that 
different viruses induce unique sets of 
costimulatory ligands that determine 
the fate of antiviral immunity. Viruses 
that specifically induce expression of 
PD-L1 and PD-L2 in antigen-present-
ing cells may downregulate the host 
immune system and persist longer, 
whereas those that induce positive 
costimulatory ligands in antigen-pre-
senting cells may elicit effective antivi-
ral immunity and disappear quickly.460 Cell 124, February 10, 2006 ©2006 EWithin one week, PD-L1-deficient 
mice succumb to LCMV-clone 13 
infection and exhibit immunopathologic 
damage. This is in apparent contradic-
tion to the beneficial effects of blocking 
the PD-1/PD-L1 interaction during the 
chronic phase of LCMV-clone 13 infec-
tion (Barber et al., 2005). Although PD-
1-deficient mice also develop severe 
hepatitis at the initial phase of adenovi-
rus infection, they recover quickly and 
their hepatocytes fully regenerate within 
30 days (Iwai et al., 2003). The reasons 
why opposite long-term effects are 
observed in PD-L1- and PD-1-deficient 
mice are probably due to a difference 
in the capacity for regeneration of the 
affected organs and the replication rate 
of the viruses in the two models.
During infection there may be a lim-
ited period of time during which the host 
immune system can eliminate the virus 
without damaging host tissue. When 
the host immune system cannot elimi-
nate viruses within that period of time, 
PD-1 expression is increased to sup-
press an excessive immune response 
that would lead to tissue destruction. 
The recent report by Chisari and col-
leagues, indicating that antiviral immu-
nity oscillates in response to hepatitis B 
virus (HBV) infection, may also support 
this scenario (Isogawa et al., 2005). 
HBV-specific CD8 T cells from an 
immune donor rapidly migrate into the 
liver, the site of HBV replication, and 
secrete interferon-γ (IFNγ), which leads 
to the suppression of HBV replication 
within 24 hr. However, following this ini-
tial phase, CD8 T cells lose the ability to 
produce IFNγ and instead begin to pro-
duce granzyme B, which leads to the 
acquisition of cytolytic activity against 
infected hepatocytes. Because PD-1 
expression is observed at the same 
time as the emergence of granzyme 
B-positive T cells and persists after the 
disappearance of viral gene expression 
at day 7, PD-1 is thought to regulate 
the oscillatory response of HBV-spe-
cific CD8 T cells (Isogawa et al., 2005). 
Further analyses may also reveal the 
involvement of PD-1 in cytokine pro-
duction, cytolytic activity, and life span 
of antiviral T cells in acute and chronic 
viral infections.
To date, many groups have reported 
that blocking the PD-1/PD-L1 interac-
tion promotes tumor immunity and lsevier Inc.that patients with tumors expressing 
PD-L1 and/or PD-L2 have a poorer 
prognosis. Antitumor T cells may also 
be exhausted by the expression of 
PD-1 because, like viral antigens dur-
ing chronic infections, tumor antigens 
persist in the host. If this is the case, 
blocking PD-1 might also reanimate 
suppressed antitumor T cells leading 
to the eradication of tumors.
As in tumor immunity and chronic 
viral infection, autoreactive T cells in 
autoimmune diseases also persistently 
encounter their antigens. Although 
PD-1-deficient mice develop autoim-
mune disorders, interestingly, different 
target organs are affected when the 
PD-1-deficient mice are backcrossed 
on different mouse strains. Whereas 
C57BL/6-PD-1-deficient mice develop 
glomerulonephritis and arthritis, BALB/
c-PD-1-deficient mice develop dilated 
cardiomyopathy and gastritis (Okazaki 
et al., 2002). In NOD mice, a murine 
model of type I diabetes, blocking the 
PD-1/PD-L1 interaction in pre-diabetic 
mice dramatically accelerates the 
onset and severity of diabetes, similar 
to that seen in NOD mice lacking PD-
1. Although diabetogenic CD8 T cells 
play a critical role in the induction of 
insulitis (the inflammation of the insu-
lin-secreting pancreatic islets), they are 
inactivated in the later phase of diabe-
tes in NOD wild-type mice. Because 
hyperactivation of CD8 T cells is one 
characteristic of the NOD mice lacking 
PD-1, diabetogenic CD8 T cells in NOD 
wild-type mice may be regulated by a 
similar mechanism that affects anti-
LCMV CD8 T cells during chronic viral 
infection (Wang et al., 2005). Although 
the current observation that anti-LCMV 
CD8 T cells are suppressed by PD-1 
in chronic infection appears similar to 
the suppression of diabetogenic CD8 T 
cells by PD-1 in pre-diabetic NOD wild-
type mice, there is a critical difference 
between these two models. Namely, 
PD-1 expression is rarely detected on 
CD8 T cells in pre-diabetic NOD wild-
type mice, whereas all of the LCMV-
specific CD8 T cells during chronic viral 
infection express PD-1. Thus, it will be 
important to analyze how the expres-
sion of PD-1, PD-L1, and PD-L2 is reg-
ulated in both autoimmunity and antivi-
ral immunity for a full understanding of 
PD-1-dependent immune regulation.
The report by Ahmed and col-
leagues opens up new possibilities for 
the treatment of chronic viral infections. 
Chronic viral infections are resistant to 
conventional medications and some-
times lead to tumorigenesis, such as 
liver cancer due to infections by HBV 
and hepatitis C virus. The invention of 
a safe and effective therapy is urgently 
needed. Interestingly, PD-1 deficiency 
leads to a relatively mild phenotype 
when compared to loss of another 
CD28 family member, CTLA-4, even 
though engagement of CTLA-4, like 
PD-1, results in the inhibition of T cell 
function. Also, the expression of PD-1 
is restricted to activated lymphocytes. 
Thus, blocking PD-1 may have fewer 
side effects than other potential thera-
pies. The next step may be to demon-When hungry, eat your sister... but 
beware that she does not eat you first! 
This is the motto of the soil bacterium 
Bacillus subtilis, according to results 
from Rich Losick’s lab, first reported 
by González-Pastor et al. (2003), and 
now further analyzed by Ellermeier et 
al. (2006) in this issue of Cell. When B. 
subtilis is subjected to starvation, two 
independant gene clusters become 
transcribed, leading to the synthesis 
and release in the external medium of 
two toxic peptides, SkfA and SdpC. 
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Before launching a missile, it i
In this issue of Cell, Ellermeie
safety net for the soil bacteriu
protein it secretes by upregu
transcriptional repressor at thstrate in human patients that antigen-
specific T cells survive during chronic 
infections, express PD-1, and are 
reanimated by blocking PD-1 signaling. 
Such findings could one day lead to 
the clinical use of PD-1 blockers for the 
treatment of chronic viral infections.
REFEREnCEs
Barber, D.L., Wherry, E.J., Masopust, D. 
Zhu, B., Allison, J.P., Sharpe, A.H., Free-
man, G.J., and Ahmed, R. (2005). Nature. 
Published online December 28, 2005. 
10.1038/nature04444.
Ishida, Y., Agata, Y., Shibahara, K., and Honjo, 
T. (1992). EMBO J. 11, 3887–3895.
Isogawa, M., Furuichi, Y., and Chisari, F.V. 
(2005). Immunity 23, 53–63.
Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., 
and Honjo, T. (2003). J. Exp. Med. 198, 39–50.Cell 124, F
Both factors kill neighboring siblings, 
thereby releasing nutrients that sus-
tain further growth of the bacteria pro-
ducing the toxins. However, in order to 
survive, these bacteria have to protect 
themselves from the toxic peptides 
they produce. The SkfA killing factor 
is pumped out of the bacterial cells 
by the products of two genes belong-
ing to the skf operon (González-Pas-
tor et al., 2003). In this issue of Cell, 
Ellermeier et al. (2006) elucidate the 
mechanism that provides protection 
 Be Killed:  
lance
RS UPR9073, 75005 Paris, France
s necessary to design an efficien
r et al. (2006) describe the mech
m Bacillus subtilis. This bacteri
lating an immunity protein, whi
e plasma membrane.Kirchberger, S., Majdic, O., Steinberger, P., 
Bluml, S., Pfistershammer, K., Zlabinger, G., 
Deszcz, L., Kuechler, E., Knapp, W., and Stockl, 
J. (2005). J. Immunol. 175, 1145–1152.
Okazaki, T., Iwai, Y., and Honjo, T. (2002). Curr. 
Opin. Immunol. 14, 779–782
Probst, H.C., McCoy, K., Okazaki, T., Honjo, T., 
and van den Broek, M. (2005). Nat. Immunol. 
6, 280–286.
Prokunina, L., and Alarcon-Riquelme, M. (2004). 
Hum. Mol. Genet. 13, R143–R148.
Sevilla, N., Kunz, S., Holz, A., Lewicki, H., 
Homann, D., Yamada, H., Campbell, K.P., de la 
Torre, J.C., and Oldstone, M.B. (2000). J. Exp. 
Med. 192, 1249–1260.
Wang, J., Yoshida, T., Nakaki, F., Hiai, H., Oka-
zaki, T., and Honjo, T. (2005). Proc. Natl. Acad. 
Sci. USA 102, 11823–11828.
Zajac, A.J., Blattman, J.N., Murali-Krishna, K., 
Sourdive, D.J., Suresh, M., Altman, J.D., and 
Ahmed, R. (1998). J. Exp. Med. 188, 2205–
2213.ebruary 10, 2006 ©2006 Elsevier Inc. 461
against the SdpC peptide and reveal 
a remarkable new signal transduction 
pathway (see Figure 1).
The core of the new signaling path-
way is an operon encoding a soluble 
DNA binding protein, SdpR, and a 
transmembrane immunity protein, 
SdpI. When nutrients are plentiful, 
the sdpRI operon is not transcribed, 
due to the presence of the global 
repressor AbrB, which also represses 
the operon encoding the SdpC toxin 
(Fujita et al., 2005). As nutrients 
t safety net for self-protection. 
anism underlying a biological 
um protects itself from a toxic 
ch it does by sequestering a 
